Antiphospholipid Antibodies in Critically Ill Patients With COVID‐19

Study (n=66) found antiphospholipid antibodies (APSA) were common (47%) in patients in critical condition (CC) but were not present among those not in CC. APSA may be transient & disappear in few weeks, but in genetically predisposed, may trigger condition similar to APS syndrome

Arthritis & Rheumatology